- Trial Phase
- Approved
- Time to Market
- Already on market since 2008
- Why 3/10
- Convenia is an already-approved, marketed drug with no pending PDUFA, pivotal readout, or other binary regulatory catalyst in the next 12 months. It is one product in Zoetis's large diversified animal health portfolio (~$8-9B annual revenue). Generic competition is a known headwind already impacting the stock. Per the rubric, an approved drug with no imminent regulatory decision scores 3-5; the lack of a hard dated catalyst and the diversified nature of Zoetis place it at 3.
Convenia is a mature, approved product facing generic erosion — a known headwind already priced into ZTS's ~50% decline from its 52-week high. The next meaningful catalyst for ZTS is its quarterly earnings (next likely in late October/November 2026), where Convenia generic impact will be visible in the companion animal segment. Investors should watch for further margin compression and market share loss to Dechra's Solovecin.
Price Chart
Executive Summary
Convenia (cefovecin sodium) is Zoetis's long-acting injectable cephalosporin antibiotic for skin infections in dogs and cats, first FDA-approved in June 2008. It was a blockbuster product for over 15 years, but the FDA approved the first generic cefovecin sodium injection on June 24, 2025, and Dechra launched Solovecin as a bioequivalent generic competitor shortly after. As an already-approved, marketed drug with no pending regulatory binary, Convenia itself has no near-term catalyst. However, the generic erosion is a known headwind for Zoetis, contributing to the stock's decline from a 52-week high of ~$155 to ~$76. Zoetis is a large diversified animal health company, so Convenia is just one product in a broad portfolio.
How It Works
Convenia is a long-acting injectable antibiotic (cephalosporin class) for dogs and cats. A single shot provides up to 14 days of antibiotic coverage against bacterial skin infections, wounds, and abscesses. It works by interfering with bacteria's cell wall formation, killing susceptible bacteria.
Trial Status
Convenia was originally FDA-approved in June 2008 (by Pfizer Animal Health, now Zoetis). It is a fully commercialized, marketed veterinary product with over 15 years of real-world use. The FDA approved the first generic cefovecin sodium injection on June 24, 2025.
The Two-Sided Case
Upcoming Catalysts
- Zoetis quarterly earnings (next likely late Oct/Nov 2026) — Convenia generic revenue erosion will show in companion animal segment results
- Further generic entrants or pricing pressure from Dechra's Solovecin
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Zoetis Inc. 8-K ZTS ·Originating report